Finn
UTHR Biotechnology · Rare disease · Profitable biotech · Pulmonary hypertension · Thesis updated August 11, 2026

Key drug filings meet flat sequential revenue

01 Running thesis

Pipeline filings arrive as legacy sales stall

The bull case is stronger on regulatory progress. The company officially submitted a new drug application for ralinepag in pulmonary arterial hypertension and a supplemental application for nebulized Tyvaso in idiopathic pulmonary fibrosis. These filings give United Therapeutics a concrete path toward major new product launches in 2027, shifting the narrative from clinical trials to commercial preparation.

The company is defending its base while waiting for these approvals. Tyvaso DPI, the dry powder inhaler version of treprostinil, continues to show growth in patient demand and offset declines in older formats. The business remains highly profitable, and management authorized a $2 billion share repurchase program earlier this year, signaling confidence and supporting per-share value.

The bear case centers on competitive pressure and execution risk. Q2 2026 revenue was $783 million, remaining flat sequentially. Nebulized Tyvaso is facing active pressure from new market options like Liquidia's Yutrepia. Management admitted that the path to a $4 billion revenue target by 2027 using only the current portfolio has narrowed.

That leaves the stock as a quality biotech with a live execution test. Finn scores show strong financial health and business performance, but lower growth and sentiment. The company has real assets, yet the market is waiting to see if the upcoming drug launches can offset legacy product declines.

Aug 2026→Q2 2026 showed flat sequential revenue of $783 million. The company submitted regulatory applications for ralinepag and Tyvaso in IPF, which management noted are now crucial to hitting the $4 billion revenue target for 2027.
May 2026→Q1 2026 showed a 2% revenue decline and a sharper drop in Nebulized Tyvaso, while Tyvaso DPI and Orenitram kept growing. The same update added a clearer growth path from positive ralinepag and TETON-1 data, but also confirmed Yutrepia as an active direct competitor.
Feb 2026▲Full-year 2025 revenue reached $3.18 billion, and management reaffirmed its $4 billion annual revenue run-rate target by 2027. Tyvaso DPI growth and a clearer launch plan supported the bull case.
Apr 2025▲The starting thesis was a profitable rare disease company with 18 straight quarters of revenue growth and a strong Tyvaso franchise. The key long-term option was xenotransplantation, while the main watch item was the path to the 2027 revenue goal.
02 Business model

Treprostinil pays the bills

United Therapeutics makes most of its money by selling rare disease drugs, mainly treprostinil-based treatments for pulmonary hypertension. Pulmonary hypertension means high blood pressure in the blood vessels of the lungs. These diseases are serious, chronic, and treated by specialists, which can support high drug prices when the medicine works.

The main defense comes from drug delivery and doctor trust. Tyvaso DPI is easier for many patients than a nebulized form, so the company has been moving patients toward the dry powder inhaler. That helps protect the franchise even as older forms, such as Remodulin and Nebulized Tyvaso, face pressure.

The weak point is concentration. If Tyvaso loses share faster than new products can launch, the revenue story gets harder. The business model now relies heavily on upcoming FDA approvals for ralinepag and Tyvaso in IPF to reach management revenue goals.

03 Product portfolio

What United sells and what comes next

Growth engine

Tyvaso DPI

This is the dry powder inhaler version of treprostinil and the company's largest growth driver, capturing patients moving away from nebulized forms.

Cash cow

Nebulized Tyvaso

This older inhaled form still matters, but it is shrinking as the mix shifts and competitive pressure increases.

Steady

Orenitram

Orenitram is an oral treprostinil treatment. It provides a steady, growing revenue stream for patients preferring oral options.

Cash cow

Remodulin

Remodulin is an infused treprostinil product. It still brings in meaningful sales but faces generic competition.

Option

Ralinepag

Ralinepag is a next wave PAH drug. The company recently submitted an NDA for this treatment, targeting a 2027 launch.

Option

Tyvaso for IPF

Tyvaso may expand into idiopathic pulmonary fibrosis. An sNDA has been submitted following positive trial results.

Option

UHeart xenotransplantation

UHeart is a long-range program that aims to use animal organs for human transplant. It has FDA clearance to start a first-in-human trial, but the path is long and uncertain.

04 Business segments

Mix remains Tyvaso-heavy

Tyvaso DPI42%modest
Nebulized Tyvaso16%declining
Orenitram17%modest
Remodulin16%declining
Other products and revenue8%flat

This mix uses Q1 2026 revenue of $781.5 million from the 10-Q, which remains representative of the heavily concentrated treprostinil product lines.

05 Risk factors

What could break the story

Yutrepia takes Tyvaso share

High impact · Medium odds

Liquidia's Yutrepia launched in June 2025 and competes directly with Tyvaso DPI and Nebulized Tyvaso. If doctors or payers push patients toward Yutrepia, United Therapeutics could lose sales and pricing power in its core franchise.

We watchTrack Tyvaso DPI growth, total Tyvaso revenue, and any payer comments about switching patients to Yutrepia.

Execution fails on new launches

High impact · Medium odds

With the 2027 revenue target now heavily reliant on ralinepag and Tyvaso for IPF, the risk has moved to FDA reviews and sales execution. A clean approval still may not mean a fast launch if doctors move slowly or reimbursement is difficult.

We watchWatch for FDA acceptance of the recent NDA submissions, label wording upon approval, and early prescription trends after launch.

Nebulized Tyvaso keeps falling

Medium impact · High odds

Nebulized Tyvaso sales have been falling due to mix shift and competition. This creates a revenue hole that the growing inhaler and upcoming drug launches must fill.

We watchCompare Tyvaso DPI growth against the decline in Nebulized Tyvaso each quarter.

Too much depends on treprostinil

High impact · Medium odds

United Therapeutics is profitable and focused, but most revenue still comes from treprostinil-based products. That focus can be a strength when the franchise grows, and a weakness if competition or safety issues hit the drug family.

We watchTrack the share of revenue from Tyvaso, Orenitram, and Remodulin versus newer non-treprostinil products.

UHeart stays far from revenue

Low impact · High odds

The UHeart xenotransplantation program is bold, but it is still very early. FDA clearance to begin a human trial is not the same as proof of safety, approval, or commercial demand.

We watchFollow first-in-human trial enrollment, safety updates, and FDA feedback before assigning material revenue value.
06 Quick answers

In one breath

What does United Therapeutics do?

United Therapeutics develops and sells rare disease medicines, mainly for pulmonary hypertension. Its biggest business is treprostinil, sold through products such as Tyvaso DPI, Nebulized Tyvaso, Orenitram, and Remodulin.

Why does Tyvaso matter so much?

Tyvaso is the company's largest product family and the main reason investors watch United Therapeutics. Tyvaso DPI is growing, but Nebulized Tyvaso is falling, so the mix shift is important.

What is the main new risk for UTHR?

The clearest new risk is Liquidia's Yutrepia. It launched in June 2025 and now competes directly with Tyvaso DPI and Nebulized Tyvaso.

What are the next big catalysts?

The next big items are FDA decisions on the newly submitted applications for ralinepag and Tyvaso in IPF, and the market response to Yutrepia. Investors should also watch the $2 billion buyback and early UHeart trial progress.

Get started with Finn today